Viatris Inc. (VTRS) Stock

Viatris Inc. (VTRS) is a Healthcare stock trading at $15.37 (as of 2026-06-18), with a market capitalization of $18.35B and a trailing P/E of -54.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Viatris Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines across multiple segments, including Developed Markets, Greater China, JANZ, and Emerging Markets. It provides brand and generic drugs, complex generics, biosimilars, and APIs for a range of therapeutic areas, selling to wholesalers, retailers, payers, insurers, governments, and institutions.

Valuation — source: SEC EDGAR (first-party)
Price	$15.37
Market Cap	$18.35B
P/E Ratio	-54.4
EV / EBITDA	10.7
Price / Book	1.30
Price / Sales	1.31
DCF Value (model)	$12.02
DCF Upside vs Price	-21.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$14.30B
Net Margin	-24.6%
Return on Equity	-2.0%
Debt / Equity	0.98
Current Ratio	1.60
Revenue Growth (YoY)	8.1%
EPS Growth (YoY)	-105.9%
FCF Growth (YoY)	-29.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	0.69 (distress)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-54.4
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-359.6%
vs Industry	-415.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($1.72B)
Institutional Holders Tracked	10
Congressional Trades (recent)	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Scott Andrew Smith
Employees	32,000
Country	US
IPO Date	1980-03-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by revenue (market cap unavailable); US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.